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BINDING OF DEXAMETHASONE BY THE SUBCELLULAR FRACTIONS OF 
MOUSE EPIDERMIS AND DERMIS 
THOMAS J. SLAGA, PH.D., SARA THOMPSON, B.S.*, AND JAMES A. ScHWARZ, B.S. 
Cancer and Toxteology Program, Bwlogy Division, Oak Ridge National Laboratory, 
Oak R idge, Tennessee , U . S. A. 
The binding of the potent anticarcinogenic agent, dexamethasone, to mouse epidermal 
and dermal subcellular fractions was investigated. When applied to mouse skin, 3H-labeled 
dexamethasone remained associated, after extensive dialysis, with epidermal and dermal 
cytosol, microsomes, mitochondria, and chromatin. The specific activity of dexamethasone 
binding to these fractions was from 2 to 5 times as high in the epidermis as in the dermis. 
Epidermal chromatin had the highest specific activity of binding. Dexamethasone was not 
associated with the cytosol protein receptor which was previously found to specifically bind 
tumor promoters and polycyclic hydrocarbon carcinogens. 
Several investigators have shown that steroidal 
anti-inflammatory agents can reduce the tumor 
response to mouse skin promoters [1-3]. Scribner 
and Slaga !4) reported a complete suppression of 
12-0-tetradecanoylphorbol-13-acetate (TPAJ tumor 
promotion by certain doses of dexamethasone for 6 
months. Recently, dexamethasone was found to 
reduce tumor initiation and complete carcinogene-
sis by 3-rnet.hylcholanthrene (MCl and 7 ,12-di-
methylbenzla)anthracene (DMBA) [5,61. Corti-
sone also was reported to reduce mouse skin tu-
mors by the complete carcinogens. benzo[a]pyrene 
BP [2], MC [ 7], and DMBA [8]. 
Dexamethasone was found to be a potent inhibi-
tor of epidermal DNA synthesis and TPA-induced 
hyperplasia 14 ,9]. It a lso reduced the concentration 
of several protein fractions as run on polyacryl-
amide gels; these were greatly enhanced after 
TPA treatment [4,10]. The binding ofphorbol ester 
tumor promoters to epidermal chromatin and a 
cytosol protein receptor was markedly suppressed 
bv the simultaneous treatment with dexametha-
s~ne in vivo [ 10). However, dexamethasone did not 
compete in vitro for TPA binding to the cytosol 
protein receptor [10]. 
Herein we describe the epidermal and dermal 
subcellular binding of dexamethasone in order to 
better understand its mechanism of inhibiting car-
cinogenesis. 
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MATERIALS AND METIWDS 
Bio-Gel P-30 was obtained from Bio-Rad Laborato-
ries, Richmond, California. Dexamethasone was pur-
chased from Sigma Chemical Co. , St. Louis, Missouri. 
Tritiated dexamethasone ([1,2,4-3H)dexamethasone; 10 
Ci/mmoleJ was obtained from Schwarz/Mann, Orange-
burg, New York. 
Female Charles River CD-1 mice were purchased 
from Charles River Mouse Farms, North Wilmington, 
Mass. Mice 7 to 9 weeks old were carefully shaved with 
surgical clippers 2 days before treatment and only those 
mice in the resting phase of the hair cycle were used in 
biochemical experiments. [3H]Dexamethasone (10 ILg; 
20 ILCi; sp act BOO mCi/mmolel in 0.2 ml of acetone was 
applied to a }I /2" x 1" area on the backs of mice with an 
automatic pipet. The binding of the radioactive steroid 
was determined at 15, 30. 60, 120, and 180 min after 
treatment. Each time point reported represents an av-
erage of2 experiments with 10 mice per experiment. 
The mice were killed by cervical dislocation, and 
Nudit cream depilatory agent was applied to the shaved 
areas. After 5 min the cream was thoroughly washed ofT 
with cold wat.er. the skins were removed and immersed 
in distilled water at 52"C for 30 sec, and immediately 
transferred to ice-cold water. The skins were spread out 
on a glass plate on ice and the epidermis removed by 
scraping once with a razor blade. The purity of the 
epidermal and dermal fractions has been reported pre-
viously Ill). 
The cytosol, microsomes, mitochondria, and chroma-
tin were isolated from epidermal and dermal material 
as previously described in detail [12]. The purities of 
the cytosol [12], microsomal (13], mitochondrial [12], 
and chromatin (11] fractions have been discussed previ-
ously. The mitochondrial fraction also contains lyso-
somes, and specific enzyme markers have not been 
determined for this fraction. The microsomal fraction 
contains the majority of aryl hydrocarbon hydroxylase 
[13], and the cytosol has very little capacity in this 
regard. The isolated chromatin fraction met all the 
criteria for purity for chromatin, as described previ-
ously [11). The unbound radioactive dexamethasone 
was removed by dialyzing the samples for 24 hr against 
a 1,000-fold excess of the buffer used in the homogeniza-
tion. The dialyzed cytosol fractions were passed 
through Bio-Gel P-30 columns with the same buffer 
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used for homogenization [0.01 M Tris-HCl (pH 8.0) con-
taining 0.01 M NaCI and 0.005 M 2-mercaptoethanol). 
This permitted complete separation of bound from un-
bound [3H)dexamethasone. The bound fraction was con-
centrated to 2 ml by ultrafiltration through a Diaflo 
UM2 membrane and analyzed by 2-step fractionation 
on DEAE-cellulose as described in detail elsewhere 
[11). Peak 1, containing the least acidic proteins, passed 
through the column without retention in the buffer 
used for homogenization. Peak 2, containing about 90% 
of the Bio-Gel P-30 protein fraction, was eluted with 
0.05 M sodium phosphate (pH 6.5) containing 1 M NaCJ. 
Both peaks were concentrated by ultraftltration before 
determining protein concentration and radioactivity. 
The peaks were also analyzed by 7% basic polyacryl-
amide gel electrophoresis as described previously [11]. 
RESULTS AND DISCUSSION 
Table I shows the total binding of [3H]dexa-
methasone, the potent inhibitor of mouse skin tu-
morigenesis, to each of the epidermal subcellular 
fractions at different times after treatment. The 
binding to which this Table and Table Il refer 
represents radioactivity associated with these 
fractions only after extensive dialysis. The specific 
activity of dexamethasone bound to all the subcel-
lular fractions reached a peak by 3 hr after treat-
ment. The chromatin fraction had the highest spe-
cific binding activity. 
The time course of binding of [3H]dexameth-
asone to mouse dermal subcellular fractions is 
shown in Table Il. The specific activity of binding 
to all the subcellular fractions also reached a peak 
by 3 hr after treatment. The dermal cytosol frac-
tion had the highest specific binding activity, but 
we were unable to isolate large enough quantities 
of chromatin from the dermis to determine the 
specific activity of binding. In general, the binding 
level to the epidermal subcellular fractions was 
about 4 times as great as to the dermal fractions. 
Similar results were obtained when MC binding to 
mouse epidermal and dermal subcellular fractions 
was investigated [11]. 
TABLE I. T ime course of [3H]ckxamethasone binding lo 
mouse epidermal subcellular fractions" 
Time 
Specific activity• 
(hrl Micro- Mitochon- Cytosol Chromatin somes dria 
0.25 1.82 4.45 2.66 16.57 
0.5 1.74 4.54 2.43 9.34 
1.0 2.23 5.77 3.34 17.39 
2.0 2.49 5.50 5.87 14.71 
3.0 2.65 6.86 3.85 41.71 
6.0 2.15 4.35 2.42 28.50 
24.0 0.45 1.42 0.86 10.42 
• Ten micrograms (20 ~-tCi) of [3 H)dexamethasone ap-
plied to each mouse. Each value is an average of 2 
experiments with 10 mice/experiment. Subcellular 
fractionation and separation of bound from unbound 
dexamethasone are detailed in Materials and Methods . 
0 Expressed as pmole/mg of protein for cytosol, mi-
crosomes, and mitochondria, and as pmole/mg of DNA 
for chromatin. 
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TABLE II. T ime course of[3H]ckxamethasone binding to 
mouse dermal subcellular fractions• 
Time Specific activity• (hr) Microsomea Mitochondria Cytosol 
0.25 0.41 1.16 0.41 
0.5 0.34 0.94 1.08 
1.0 0.64 1.35 1.03 
2.0 0.96 1.15 0.98 
3.0 0.72 1.47 2.28 
6.0 0.43 1.10 1.65 
24.0 0.24 0.43 0.86 
• Ten micrograms (20 ~-tCD of [3H)dexamethasone ap-
plied to each mouse. Each value is an average of 2 
experiments with 10 mice/experiment. Subcellular 
fractionation and separation of bound from unbound 
dexamethasone are detailed in Materials and Methods. 
b Expressed as pmole/mg of protein. 
TABLE III. Further fractionation of epidermal and 
dermal cytosol from mice treated with 
r 'H]dexamethasone" 
Time 
Chrl 
0.25 
0.5 
1.0 
2.0 
3.0 
6.0 
24.0 
Specific activity of cytosol after DEAE-cellulose 
2-step fractionation • 
Epidennis Dennis 
Peak I Peak 2 Peak I Peak 2 
1.43 0.17 No·· 0.036 
1.30 0.14 ND 0.032 
0.91 0.22 ND 0.031 
0.48 0.22 ND 0.048 
0.63 0.31 ND 0.051 
0.44 0.20 ND 0.035 
0.22 0.11 ND 0.015 
" Ten micrograms (20 ~-tCil of 13H)dexamethasone ap-
plied to each mouse. Each value is an average of 2 
experiments with 10 mice/experiment. 
b Specific activity expressed as pmole/mg of protein. 
The dialyzed cytosol was subjected to gel filtration and 
ultrafiltration before being analyzed on DEAE-cellu-
lose. See Materials and Methods for details . 
r No radioactivity detected. 
The dialyzed epidermal and dermal cytosol frac-
tions from the [3H]dexamethasone-treated mice 
were further fractionated by gel filtration, ultrafil-
tration, and by a 2-step fractionation on a DEAE-
cellulose column. The DEAE-cellulose fractiona-
tion is shown in Table Ill. The specific activity of 
dexamethasone binding to epidermal cytosol was 
greater in peak 1 than peak 2. Similar results were 
earlier noted with MC lll]. No detectable radioac-
tivity from dermal cytosol was found in peak 1. 
Peak 2 from epidermal cytosol contains the cytosol 
receptor protein which we have shown to bind 
phorbol ester tumor promoters [10] and MC [11) 
with some degree of specificity. The binding of 
phorbol ester tumor promoters to this receptor 
protein in peak 2, which was further purified by 
gel electrophoresis, was previously shown to be 
markedly suppressed by the simultaneous treat-
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ment with dexamethasone in vivo [10]. When peak 
2 from the [3H]dexamethasone-treated mice was 
further analyzed by 7% basic polyacrylamide gel 
electrophoresis, no radioactivity was detected in 
the protein fraction that contained the tumor pro-
moter receptor protein [10]. 
The cytosol receptor protein of the mouse epider-
mis, which physically binds the carcinogen MC 
[11] and the phorbol ester tumor promoters [10], 
appears to be a protein other than the mouse skin 
h-protein [14) or ligandin [15]. When the pro-
moter- or carcinogen-bound cytosol is applied to a 
DEAE-cellulose column and eluted in a 2-step 
procedure, the cytosol receptor protein is associ-
ated with the acidic protein fraction (peak 2), 
whereas h-protein is found in the basic protein 
fraction (peak 1). Because of the similarity in 
physical properties between h-protein and ligan-
din, Kuroki and Heidelberger 116] suggested that 
the two species might be identical. Ligandin binds 
corticosteroids and their anionic metabolites as 
well as bilirubin, cholecystographic agents, and 
certain carcinogens [15]. 
As we have shown, dexamethasone did not com-
pete in vitro for phorbol ester binding to the epi-
dermal cytosol receptor protein but did inhibit 
promoter binding in vivo [10]. Based on the above 
results plus the results of the current investiga-
tion, we have to conclude that when dexametha-
sone is given simultaneously with a phorbol ester 
tumor promoter in vivo, it is affecting the physical 
binding of the tumor promoter in an indirect man-
ner. We are presently investigating other specific 
sites of dexamethasone binding such as the typical 
glucocorticoid receptor found in several tissues 
[17 ,18] which may have some indirect influence on 
phorbol ester tumor promoter binding to its cytosol 
receptor. 
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